Non-Clinical Trials Market to Grow with a CAGR of 6.22% through 2028
Outsourcing of
non-clinical trial services to specialized Contract Research Organizations are
expected to drive the Global Non-Clinical Trials Market growth in the forecast period,
2024-2028.
According
to TechSci Research report, “Non-Clinical Trials Market – Global Industry
Size, Share, Trends, Competition Forecast & Opportunities, 2028”,
the Global Non-Clinical Trials Market stood at USD 9.86 billion in 2022 and is
anticipated to grow with a CAGR of 6.22% in the forecast period, 2024-2028, The Global
Non-Clinical Trials Market is experiencing unprecedented growth and
transformation, fueled by several key market drivers that are reshaping the
landscape of pharmaceutical and healthcare industries. Non-clinical trials,
also known as preclinical trials, play an instrumental role in evaluating the
safety, efficacy, and toxicity of experimental drugs and medical devices before
they progress to human testing. One
of the foremost drivers of the Global Non-Clinical Trials Market is the
escalating demand for groundbreaking pharmaceuticals and medical devices. As
the prevalence of various diseases continues to rise, so does the need for
innovative therapies and treatments. This has led pharmaceutical and
biotechnology companies, as well as academic research institutions, to invest
heavily in non-clinical trials to ensure that their products meet rigorous
regulatory standards and are safe for human use.The outsourcing of non-clinical
trial services to specialized Contract Research Organizations (CROs) has become
a prevalent trend in the pharmaceutical and healthcare industries. CROs offer
expertise, infrastructure, and cost-effectiveness, making them an attractive option
for companies looking to conduct non-clinical trials efficiently. This
outsourcing trend has significantly contributed to the market's growth, as CROs
play a vital role in conducting these trials on behalf of pharmaceutical giants
and emerging biotech companies.
Technological
advancements are revolutionizing non-clinical trials. In silico modeling,
artificial intelligence, and machine learning are increasingly being used to
simulate drug behavior, toxicity, and efficacy. These cutting-edge technologies
enable researchers to make more accurate predictions and reduce the reliance on
extensive animal testing. By leveraging these tools, pharmaceutical companies
can streamline the drug development process, ultimately accelerating
time-to-market. Regulatory agencies worldwide, including the U.S. Food and Drug
Administration (FDA) and the European Medicines Agency (EMA), have implemented
stringent guidelines for non-clinical trials. These regulations require
comprehensive testing and documentation of a product's safety profile before it
can advance to clinical trials. Meeting these regulatory standards is paramount
for market approval, and the demand for compliance services is driving the
growth of the Global Non-Clinical Trials Market.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on
"Global Non-Clinical Trials Market”
The
biotechnology sector has witnessed remarkable growth in recent years, with a
focus on developing innovative therapies, including gene therapies, cell-based
therapies, and biologics. These advanced therapies require extensive
non-clinical testing to ensure their safety and efficacy. Consequently, the
expansion of the biotechnology sector is a significant driver for the Global
Non-Clinical Trials Market. The paradigm of
healthcare is shifting towards personalized medicine, which tailors’ treatments
to individual patients based on their genetic makeup and specific needs.
Non-clinical trials play a pivotal role in the development of personalized
therapies, as they help identify patient-specific responses, adverse effects,
and optimal dosages. This growing emphasis on personalized medicine is spurring
an increase in non-clinical trial activities, driving the market forward.
The Global Non-Clinical
Trials Market is segmented into Study Type, Therapeutic Area, end-users,
regional distribution, and company.
Based on study
type, the Global Non-Clinical Trials Market is segmented into Pharmacodynamics (PD) studies, Pharmacokinetics (PK)
studies, and Toxicology studies. Based
on the treatment, the Toxicology studies segment emerged as the dominant
segment in the global market for Global Non-Clinical Trials Market in 2022.
Toxicology studies are a fundamental component of non-clinical trials, and they
are conducted to assess the safety of drugs and medical devices. These studies
involve evaluating the potential toxicity of a substance by examining its
effects on living organisms, typically using animal models. The goal is to identify any adverse effects, establish
safe dosage levels, and understand the potential risks associated with the
product under investigation.
Based on route
of Therapeutic Area, the Global Non-Clinical Trials Market is segmented into Oncology, Cardiovascular, Neurology, Immunology, Others.
Based on the therapeutic area, the oncology segment emerged as the dominant
player in the global market for Global Non-Clinical Trials Market in 2022. Oncology, which focuses on the study and
treatment of cancer, has been a major area of emphasis in pharmaceutical and
biomedical research due to the significant global burden of cancer.
Non-clinical trials in oncology involve the preclinical evaluation of potential
cancer therapies, including novel drugs, immunotherapies, targeted therapies,
and various treatment modalities such as chemotherapy and radiation therapy. The high prevalence of cancer and the constant quest
for more effective and personalized cancer treatments have driven extensive
research and development efforts in the field. Non-clinical trials play a
pivotal role in assessing the safety and efficacy of these oncology treatments
before they advance to human clinical trials. These trials involve evaluating
the impact of potential cancer therapies on tumor growth, metastasis, and
overall patient outcomes, while also assessing potential side effects and
toxicities.
North America
emerged as the dominant player in the global Non-Clinical Trials Market in 2022, holding the largest market share. North
America, particularly the United States, is home to a thriving pharmaceutical
and biotechnology sector. The region boasts a large number of pharmaceutical
companies, biotech startups, and research institutions that conduct extensive
non-clinical trials. These organizations invest heavily in research and
development, driving the demand for non-clinical trial services. The region has access to cutting-edge technologies and
research infrastructure, including state-of-the-art laboratories and advanced
imaging facilities. These resources enable the execution of complex
non-clinical trials and contribute to the region's dominance in the market.
Major companies
operating in Global Non-Clinical Trials Market are:
- Labcorp Drug Development
- Charles River Laboratories
- PPD (Pharmaceutical Product Development)
- ICON plc
- Novartis AG
- Merck & Co., Inc.
- AstraZeneca plc
- Cmic Holdings Co., Ltd
- ProPharma
- MorphoSys AG
Download Free Sample Report
Customers can
also request for 10% free customization on this report.
“The Global
Non-Clinical Trials Market is poised for substantial growth in the coming
years, driven by several overarching factors. Firstly, the relentless demand
for innovative pharmaceuticals and medical devices, propelled by the rising
global burden of diseases, is a primary growth catalyst. This demand
necessitates comprehensive non-clinical trials to ensure the safety and
efficacy of these advanced treatments before they reach patients. Also, the
strategic outsourcing of non-clinical trial services to Contract Research
Organizations (CROs) is a prominent trend that is expected to continue fueling
market expansion. Pharmaceutical and biotechnology companies increasingly rely
on CROs to leverage specialized expertise, state-of-the-art facilities, and
cost-effective trial management, streamlining the drug development process. Furthermore,
the adaptation of regulatory frameworks to accommodate innovative approaches
and alternative testing methods is fostering flexibility and efficiency in
non-clinical trials. This regulatory evolution is expected to encourage
researchers to explore new avenues and embrace cutting-edge technologies.” said
Mr. Karan Chechi, Research Director with TechSci Research, a research-based
management consulting firm.
“Non-Clinical
Trials Market - Global Industry Size,
Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Study Type
(Pharmacodynamics (PD) studies, Pharmacokinetics (PK) studies, Toxicology
studies), By Test (In silico, In vitro, In vivo ), By Therapeutic Area
(Oncology, Cardiovascular, Neurology, Immunology, Others), By End User
(Pharmaceutical and Biotechnology Companies, Contract Research Organizations
(CROs), Academic and Government Research Institutes, Others ) By Region and
Competition”, has evaluated the future growth potential of Global
Non-Clinical Trials Market and provides statistics & information on market
size, structure and future market growth. The report intends to provide
cutting-edge market intelligence and help decision makers take sound investment
decisions. Besides, the report also identifies and analyzes the emerging trends
along with essential drivers, challenges, and opportunities in Global Non-Clinical
Trials Market.
Contact
Mr. Ken Mathews
708 Third
Avenue,
Manhattan, NY,
New York 10017
Tel:
+1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com